The French Blood Agency announces agreement with TreeFrog Therapeutics to scale-up manufacturing of iPS-derived hematopoietic stem cell transplants

TreeFrog Therapeutics will apply its proprietary technology for the mass-production of stem cell therapies to the world-first single-step protocol allowing the differentiation of human induced pluripotent stem cells (iPSCs) into fully functional human hematopoietic stem cells (HSCs). Resulting off-the-shelf universal HSC grafts could reduce costs...